Real World Patient-Reported Outcomes in Chinese Her2+ Early Breast Cancer Patients Receiving (Neo) Adjuvant Anti-Her2 Based Therapy
Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY
This is a non-interventional observational, multi-center cohort study to evaluate patient-reported outcomes in Chinese HER2+ early breast cancer patients undergoing (neo) adjuvant anti-HER2 based therapy and describe changes over time, from baseline to 12 months.
Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Healthy Volunteers: f
View:
• Patients aged ≥18 years;
• Women;
• Have signed the informed consent form as per local regulations;
• Newly diagnosed with non-metastatic breast cancer (stage I-II-III, HER2+) at the time of starting anti-HER2 therapy;
• Be able to comply with the follow-up visits, assessments, answering questionnaires.
Locations
Other Locations
China
Keda Yu
RECRUITING
Shanghai
Contact Information
Primary
Keda Yu, MD, PhD
yukeda@fudan.edu.cn
+8618017317597
Time Frame
Start Date: 2023-10-26
Estimated Completion Date: 2025-04
Participants
Target number of participants: 600
Related Therapeutic Areas
Sponsors
Leads: Fudan University